Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

More than 1000 people -- shoulder-to-shoulder in bleachers, on the ground and on folding chairs -- jammed the Clackamas ...

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

(HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online in JAMA Surgery.

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs ...